Xenon Pharmaceuticals (XENE) Long-Term Debt Issuances (2018)
Xenon Pharmaceuticals (XENE) posted quarterly Long-Term Debt Issuances of $3.5 million for Q3 2018.
Xenon Pharmaceuticals (XENE) Long-Term Debt Issuances (2018) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Long-Term Debt Issuances for 1 consecutive years, with $3.5 million the latest figure, recorded in Q3 2018.
- In Q3 2018, Long-Term Debt Issuances changed N/A year-over-year to $3.5 million; the TTM figure through Dec 2020 stood at $3.5 million (changed N/A YoY), while the FY2020 annual figure was -$16.7 million, changed N/A from the prior year.
- Long-Term Debt Issuances steadied at $3.5 million in Q3 2018 per XENE's latest filing.
- Across five years, Long-Term Debt Issuances topped out at $3.5 million in Q3 2018 and bottomed at $3.5 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 3.46 Mn |
| Sep 30, 2018 | 3.46 Mn |